Q32 Bio (NASDAQ:QTTB) Research Coverage Started at HC Wainwright

HC Wainwright started coverage on shares of Q32 Bio (NASDAQ:QTTB) in a report issued on Wednesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $13.00 price objective on the stock. HC Wainwright also issued estimates for Q32 Bio’s Q4 2025 earnings at ($0.63) EPS, FY2025 earnings at ($2.91) EPS, FY2026 earnings at ($2.53) EPS, FY2027 earnings at ($2.43) EPS, FY2028 earnings at ($2.19) EPS, FY2029 earnings at ($0.18) EPS and FY2030 earnings at $0.11 EPS.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Q32 Bio in a research note on Friday, January 9th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Q32 Bio currently has an average rating of “Hold” and an average price target of $14.00.

Q32 Bio Trading Down 4.2%

Shares of QTTB stock opened at $4.56 on Wednesday. The stock has a market capitalization of $56.11 million, a price-to-earnings ratio of -1.33 and a beta of 0.16. Q32 Bio has a 12-month low of $1.35 and a 12-month high of $6.37. The stock’s 50-day moving average price is $3.81 and its 200-day moving average price is $2.90.

Insider Activity at Q32 Bio

In other news, CEO Jodie Pope Morrison sold 9,896 shares of Q32 Bio stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $4.51, for a total value of $44,630.96. Following the completion of the transaction, the chief executive officer owned 89,104 shares in the company, valued at approximately $401,859.04. The trade was a 10.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Lee Kalowski sold 9,072 shares of the business’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $3.46, for a total value of $31,389.12. Following the transaction, the chief financial officer directly owned 39,938 shares in the company, valued at approximately $138,185.48. This represents a 18.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 48,284 shares of company stock worth $184,604 over the last three months. 40.00% of the stock is currently owned by insiders.

Institutional Trading of Q32 Bio

Institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP bought a new position in Q32 Bio during the second quarter valued at $25,000. Acadian Asset Management LLC purchased a new position in shares of Q32 Bio during the 1st quarter worth about $50,000. Two Sigma Investments LP bought a new position in Q32 Bio during the 3rd quarter valued at about $62,000. ADAR1 Capital Management LLC purchased a new stake in Q32 Bio in the 4th quarter worth about $66,000. Finally, AQR Capital Management LLC bought a new stake in Q32 Bio in the first quarter worth about $68,000. 31.32% of the stock is currently owned by institutional investors.

Key Q32 Bio News

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $13 price target, providing a long‑term constructive view that can support upside versus current levels. HC Wainwright Begins Coverage on Q32 Bio
• Neutral Sentiment: HC Wainwright published a multi‑year forecast showing improving EPS over time and an eventual transition to modest profitability in FY2030 (EPS $0.11), which is a positive directional signal but depends on successful clinical and commercial execution.
• Negative Sentiment: The analyst model shows substantial near‑term losses: Q4 2025 EPS of ($0.63) and FY2025–FY2028 EPS ranging from about ($2.91) to ($2.19). These projected deficits increase financing and execution risk and likely weigh on short‑term investor sentiment.
• Negative Sentiment: Consensus full‑year earnings remain deeply negative (current consensus ~($12.32) per share), indicating the market and other analysts expect much larger near‑term losses than HC Wainwright’s more optimistic runway—this divergence may temper the impact of the Buy rating.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.